Brief: Lumiradx Reports Use For Its Covid-19 Antigen Test Has Been Expanded To Include Asymptomatic Individuals
01/11/2021 22:25
Nov 1 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX ANNOUNCES THE INTENDED USE FOR ITS FDA EUA
AUTHORIZED
HIGH SENSITIVITY COVID-19 ANTIGEN TEST HAS BEEN EXPANDED TO
INCLUDE TESTING OF ASYMPTOMATIC INDIVIDUALS
* LUMIRADX LTD - MICROFLUIDIC IMMUNOFLUORESCENCE ASSAY
AUTHORIZED
FOR SCREENING ASYMPTOMATIC INDIVIDUALS USING A SINGLE TEST
Source text for Eikon: ID:nPn57xy9Ga
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing